FundaMental Pharma

FundaMental Pharma is engaged in pioneering research around a breakthrough molecular mechanism that allows to safely counteract glutamate neurotoxicity (also known as excitotoxicity) by specifically targeting the interface between NMDA receptors and TRPM4 channels with small molecule TwinF interface inhibitors (Yan et al., Science 2020). TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration. Our initial focus is on amyotrophic lateral sclerosis (ALS). The applicability of our molecules extends to a range of neurogenerative disorders including Alzheimers disease (AD)

Fundamental pharma operates in the Biotechnology research industry.

Fundamental pharma's revenue is 1m - 10m

Fundamental pharma has 11 - 50 employees.